Introduction:

Treatment with phosphodiesterase 5 inhibitors in patients with acquired and congenital heart disease, with pulmonary hypertension, can improve the quality and prognosis of life, both in surgical and non-surgical heart disease, with severe pulmonary hypertension.

Objectives:

To analyze the results of sildenafil monotherapy in surgical and non-surgical patients, with congenital and acquired heart disease and severe pulmonary hypertension.

Method:

Descriptive study in 60 patients who received sildenafil for severe pulmonary arterial hypertension, secondary to congenital left acquired heart disease. It was observed: dose, duration of treatment, tolerance, clinical and echocardiographic evolution, functional class and surgical treatment according to cardiac catheterization results.

Results:

In the period between December 2017 and December 2018, 20 patients with left heart valvular disorders, 8 congenital and 3 primary cardiac tumors, with sildenafil daily administration doses of 100 to 150 milligrams, were operated with severe pulmonary arterial hypertension. There were 29 other patients with heart disease, which although they were not surgical, improved their quality and prognosis of life.

Conclusions:

The prescription of sildenafil was useful to improve the quality and prognosis of life, both in surgical and non-surgical patients with heart disease and severe pulmonary hypertension.

        · |     · |     · ( pdf )